Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Liu E, et al. Among authors: brashear hr. Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24. Neurology. 2015. PMID: 26208959 Free PMC article. Clinical Trial.
Severe circumscribed cortical atrophy in Huntington's disease.
Garrett WT, Brashear HR, Cail WS, Lovell MA, Clayton MT, Harrison MB. Garrett WT, et al. Among authors: brashear hr. Neurology. 1998 Aug;51(2):638-9. doi: 10.1212/wnl.51.2.638. Neurology. 1998. PMID: 9710061 No abstract available.
Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C; GAL-INT-26 Study Group. Auchus AP, et al. Among authors: brashear hr. Neurology. 2007 Jul 31;69(5):448-58. doi: 10.1212/01.wnl.0000266625.31615.f6. Neurology. 2007. PMID: 17664404 Clinical Trial.
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Sperling RA, et al. Among authors: brashear hr. Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Alzheimers Dement. 2011. PMID: 21784348 Free PMC article. Review.
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. Sperling R, et al. Among authors: brashear hr. Lancet Neurol. 2012 Mar;11(3):241-9. doi: 10.1016/S1474-4422(12)70015-7. Epub 2012 Feb 3. Lancet Neurol. 2012. PMID: 22305802 Free PMC article.
MR imaging features of amyloid-related imaging abnormalities.
Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M. Barakos J, et al. Among authors: brashear hr. AJNR Am J Neuroradiol. 2013 Oct;34(10):1958-65. doi: 10.3174/ajnr.A3500. Epub 2013 Apr 11. AJNR Am J Neuroradiol. 2013. PMID: 23578674 Free PMC article.
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members. Vellas B, et al. Among authors: brashear hr. Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007. Alzheimers Dement. 2013. PMID: 23809364
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. Among authors: brashear hr. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
101 results